Share Price and Basic Stock Data
Last Updated: January 2, 2026, 1:41 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gayatri BioOrganics Ltd operates in the chemicals sector, focusing on organic cellulose derivatives. The company’s recent financial performance has been challenging, with revenue trends reflecting a significant decline. Reported sales for the fiscal year ending March 2023 were ₹1.67 Cr, a stark contrast to the ₹213.97 Cr recorded in March 2014. This decline highlights a drastic reduction in operational activity, as the company reported zero sales for multiple quarters, including September 2022, June 2023, and the subsequent periods leading into 2024. The company’s ability to generate consistent revenue has been compromised, raising concerns about its operational viability and market positioning. The absence of revenue generation in several quarters indicates a need for strategic reevaluation and potential reentry into the market. The decline in sales is compounded by the significant changes in the operational environment, emphasizing the importance of innovation and market responsiveness for future growth.
Profitability and Efficiency Metrics
Profitability metrics for Gayatri BioOrganics Ltd indicate persistent challenges. The company reported a net profit of -₹0.80 Cr for the year ending March 2023, continuing a trend of losses that has been evident over several years. The operating profit margin (OPM) for March 2023 was recorded at -46.11%, showcasing significant operational inefficiencies. Additionally, the interest coverage ratio (ICR) stood at -1.62, reflecting the company’s inability to meet interest obligations from its earnings. This financial strain is further illustrated by the return on capital employed (ROCE), which declined to -54.61% in March 2023, indicating that the company is not effectively utilizing its capital to generate profits. The negative profitability landscape raises concerns about the sustainability of the business model and the need for urgent corrective measures to enhance operational efficiency and restore profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Gayatri BioOrganics Ltd reflects significant financial distress. As of March 2025, the company’s reserves stood at -₹115.16 Cr, indicating a negative equity position that raises red flags for investor confidence. The total borrowings were reported at ₹37.29 Cr, which, when considered in conjunction with the negative reserves, suggests a precarious financial situation. The debt-to-equity ratio remains concerning at -1.03, indicating that the company has more liabilities than equity, a scenario that could deter potential investors. Furthermore, the current ratio is a mere 0.04, well below the typical benchmark of 1.5 for financial stability, indicating liquidity issues that could hinder operational capabilities. The reported book value per share was -₹4.55, further emphasizing the negative equity situation. These metrics highlight the urgent need for financial restructuring to stabilize the company’s balance sheet and improve overall financial health.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gayatri BioOrganics Ltd reveals a shift in ownership dynamics. As of March 2025, the promoters hold a reduced stake of 21.59%, a significant drop from 40.63% in December 2022. This decline raises concerns regarding promoter confidence in the company’s future prospects. Conversely, public ownership has increased to 77.77%, indicating a potential shift in investor sentiment towards the company, although it may also reflect a lack of confidence from institutional investors, as foreign institutional investors (FIIs) hold only 0.01%, while domestic institutional investors (DIIs) account for 0.65%. The total number of shareholders decreased to 32,123 as of September 2025, suggesting a potential exit of investors amid ongoing financial challenges. This evolving shareholding pattern, combined with the company’s financial struggles, may impact future capital raising efforts and investor sentiment towards the stock.
Outlook, Risks, and Final Insight
The outlook for Gayatri BioOrganics Ltd remains tenuous given the current financial metrics and operational challenges. Key risks include the ongoing negative profitability, high levels of debt relative to equity, and severe liquidity constraints, which could limit the company’s ability to invest in growth or operational improvements. Additionally, the drastic decline in promoter shareholding may signal a lack of confidence in the company’s strategic direction. Conversely, if the company can successfully implement a turnaround strategy that includes operational efficiency improvements and market re-entry, there is potential for recovery. However, this requires decisive management action and possibly restructuring to restore investor confidence and stabilize financial health. The path forward will depend heavily on the company’s ability to navigate these challenges effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gayatri BioOrganics Ltd | 126 Cr. | 15.9 | 20.0/5.35 | 4.62 | 0.00 % | 40.7 % | % | 10.0 | |
| Industry Average | 126.00 Cr | 15.90 | 0 | 4.62 | 0.00% | 40.70% | 0% | 10.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 1.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.24 | 0.12 | 2.31 | 0.18 | 0.07 | 0.10 | 0.18 | 0.15 | 0.11 | 0.08 | 0.10 | 0.18 | 0.12 |
| Operating Profit | -0.24 | -0.12 | -0.64 | -0.18 | -0.07 | -0.10 | -0.18 | -0.15 | -0.11 | -0.08 | -0.10 | -0.18 | -0.12 |
| OPM % | -38.32% | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.03 | 0.02 | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 | 0.08 | 0.07 | 0.08 | 0.09 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.24 | -0.12 | -0.67 | -0.20 | -0.11 | -0.14 | -0.23 | -0.21 | -0.18 | -0.16 | -0.17 | -0.26 | -0.21 |
| Tax % | 87.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.45 | -0.12 | -0.67 | -0.20 | -0.11 | -0.14 | -0.23 | -0.21 | -0.18 | -0.16 | -0.17 | -0.26 | -0.21 |
| EPS in Rs | -0.06 | -0.02 | -0.09 | -0.03 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 | -0.03 | -0.03 |
Last Updated: December 26, 2025, 8:16 pm
Below is a detailed analysis of the quarterly data for Gayatri BioOrganics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Expenses, as of Sep 2025, the value is 0.12 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.18 Cr. (Jun 2025) to 0.12 Cr., marking a decrease of 0.06 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.12 Cr.. The value appears strong and on an upward trend. It has increased from -0.18 Cr. (Jun 2025) to -0.12 Cr., marking an increase of 0.06 Cr..
- For OPM %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.08 Cr. (Jun 2025) to 0.09 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.21 Cr.. The value appears strong and on an upward trend. It has increased from -0.26 Cr. (Jun 2025) to -0.21 Cr., marking an increase of 0.05 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -0.21 Cr.. The value appears strong and on an upward trend. It has increased from -0.26 Cr. (Jun 2025) to -0.21 Cr., marking an increase of 0.05 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.03. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 213.97 | 255.89 | 137.22 | 79.32 | 173.32 | 155.48 | 0.00 | 0.00 | 0.00 | 1.67 | 0.00 | 0.00 | 0.00 |
| Expenses | 201.10 | 240.58 | 162.03 | 128.53 | 197.18 | 159.09 | 0.61 | 0.50 | 0.50 | 2.44 | 0.53 | 0.45 | 0.48 |
| Operating Profit | 12.87 | 15.31 | -24.81 | -49.21 | -23.86 | -3.61 | -0.61 | -0.50 | -0.50 | -0.77 | -0.53 | -0.45 | -0.48 |
| OPM % | 6.01% | 5.98% | -18.08% | -62.04% | -13.77% | -2.32% | -46.11% | ||||||
| Other Income | 0.30 | 1.27 | 0.96 | -16.53 | 11.87 | 2.10 | 85.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 7.57 | 9.39 | 12.74 | 11.57 | 0.19 | 4.71 | 0.01 | 0.00 | 0.00 | 0.03 | 0.15 | 0.28 | 0.32 |
| Depreciation | 4.25 | 2.37 | 2.13 | 5.34 | 6.96 | 9.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 1.35 | 4.82 | -38.72 | -82.65 | -19.14 | -15.51 | 84.47 | -0.50 | -0.50 | -0.80 | -0.68 | -0.73 | -0.80 |
| Tax % | 0.00% | 18.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 26.25% | 0.00% | 0.00% | |
| Net Profit | 1.35 | 3.93 | -38.73 | -82.65 | -19.14 | -15.51 | 84.47 | -0.50 | -0.50 | -1.01 | -0.68 | -0.73 | -0.80 |
| EPS in Rs | 0.27 | 0.77 | -6.27 | -10.49 | -2.43 | -1.97 | 10.72 | -0.06 | -0.06 | -0.13 | -0.09 | -0.09 | -0.10 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 191.11% | -1085.50% | -113.40% | 76.84% | 18.97% | 644.62% | -100.59% | 0.00% | -102.00% | 32.67% | -7.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1276.61% | 972.10% | 190.24% | -57.88% | 625.65% | -745.21% | 100.59% | -102.00% | 134.67% | -40.03% |
Gayatri BioOrganics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -8% |
| 3 Years: | -19% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 18% |
| 3 Years: | 3% |
| 1 Year: | 103% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 3:31 pm
Balance Sheet
Last Updated: December 4, 2025, 2:56 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 50.92 | 50.92 | 61.78 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 |
| Reserves | -44.79 | -40.86 | -79.58 | -159.93 | -181.20 | -195.74 | -111.27 | -111.77 | -112.26 | -113.27 | -113.95 | -114.68 | -115.16 |
| Borrowings | 75.47 | 88.12 | 115.50 | 35.11 | 35.11 | 35.11 | 35.11 | 35.11 | 35.11 | 35.66 | 36.36 | 36.90 | 37.29 |
| Other Liabilities | 94.72 | 43.94 | 44.00 | 150.81 | 212.77 | 226.93 | 0.46 | 0.47 | 0.60 | 0.44 | 0.37 | 0.66 | 0.75 |
| Total Liabilities | 176.32 | 142.12 | 141.70 | 104.78 | 145.47 | 145.09 | 3.09 | 2.60 | 2.24 | 1.62 | 1.57 | 1.67 | 1.67 |
| Fixed Assets | 48.88 | 47.19 | 45.69 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.37 | 5.80 | 6.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 127.07 | 89.13 | 90.00 | 104.78 | 145.47 | 145.09 | 3.09 | 2.60 | 2.24 | 1.62 | 1.57 | 1.67 | 1.67 |
| Total Assets | 176.32 | 142.12 | 141.70 | 104.78 | 145.47 | 145.09 | 3.09 | 2.60 | 2.24 | 1.62 | 1.57 | 1.67 | 1.67 |
Below is a detailed analysis of the balance sheet data for Gayatri BioOrganics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 78.79 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 78.79 Cr..
- For Reserves, as of Sep 2025, the value is -115.16 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -114.68 Cr. (Mar 2025) to -115.16 Cr., marking a decline of 0.48 Cr..
- For Borrowings, as of Sep 2025, the value is 37.29 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 36.90 Cr. (Mar 2025) to 37.29 Cr., marking an increase of 0.39 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.75 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.66 Cr. (Mar 2025) to 0.75 Cr., marking an increase of 0.09 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1.67 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.67 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1.67 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.67 Cr..
- For Total Assets, as of Sep 2025, the value is 1.67 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.67 Cr..
However, the Borrowings (37.29 Cr.) are higher than the Reserves (-115.16 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -62.60 | -72.81 | -140.31 | -84.32 | -58.97 | -38.72 | -35.72 | -35.61 | -35.61 | -36.43 | -36.89 | -37.35 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 162.69 | 63.12 | 116.05 | 6.95 | 3.18 | 1.22 | 54.64 | |||||
| Inventory Days | 51.08 | 62.87 | 98.30 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Days Payable | 177.53 | 58.80 | 79.17 | |||||||||
| Cash Conversion Cycle | 36.24 | 67.19 | 135.18 | 6.95 | 3.18 | 1.22 | 54.64 | |||||
| Working Capital Days | -18.12 | 5.32 | -103.13 | -365.55 | -212.09 | -271.31 | -7,048.65 | |||||
| ROCE % | 10.65% | 14.68% | -27.28% | -209.87% | -21.01% | -26.53% | -54.61% | -44.54% | -40.72% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Large & Midcap Fund | 452,200 | 0 | 0.55 | 452,200 | 2025-04-22 15:56:50 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -72.65 | -0.09 | -0.13 | -0.06 | -0.06 |
| Diluted EPS (Rs.) | -72.65 | -0.09 | -0.13 | -0.06 | -0.06 |
| Cash EPS (Rs.) | -0.09 | -0.08 | -0.12 | -0.06 | -0.06 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -4.55 | -4.46 | -4.38 | -4.25 | -4.18 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -4.55 | -4.46 | -4.38 | -4.25 | -4.18 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 |
| PBDIT / Share (Rs.) | -0.05 | -0.06 | -0.09 | -0.06 | -0.06 |
| PBIT / Share (Rs.) | -0.05 | -0.06 | -0.09 | -0.06 | -0.06 |
| PBT / Share (Rs.) | -0.09 | -0.08 | -0.10 | -0.06 | -0.06 |
| Net Profit / Share (Rs.) | -0.09 | -0.08 | -0.12 | -0.06 | -0.06 |
| PBDIT Margin (%) | 0.00 | 0.00 | -46.06 | 0.00 | 0.00 |
| PBIT Margin (%) | 0.00 | 0.00 | -46.06 | 0.00 | 0.00 |
| PBT Margin (%) | 0.00 | 0.00 | -47.72 | 0.00 | 0.00 |
| Net Profit Margin (%) | 0.00 | 0.00 | -60.60 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 1.38 | 1.65 | 2.38 | 1.56 | 1.58 |
| Return On Assets (%) | -43.67 | -43.18 | -62.54 | -22.19 | -19.17 |
| Long Term Debt / Equity (X) | -0.09 | -0.08 | -0.06 | -0.05 | -0.05 |
| Total Debt / Equity (X) | -1.03 | -1.03 | -1.03 | -1.05 | -1.06 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.86 | 0.00 | 0.00 |
| Current Ratio (X) | 0.04 | 0.04 | 0.04 | 0.06 | 0.07 |
| Quick Ratio (X) | 0.04 | 0.04 | 0.04 | 0.06 | 0.07 |
| Interest Coverage Ratio (X) | -1.62 | -3.56 | -27.83 | -1652.67 | -496.40 |
| Interest Coverage Ratio (Post Tax) (X) | -1.62 | -3.56 | -35.61 | -1652.67 | -496.40 |
| Enterprise Value (Cr.) | 90.61 | 75.80 | 92.13 | 182.80 | 85.41 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 55.25 | 0.00 | 0.00 |
| EV / EBITDA (X) | -201.50 | -142.51 | -119.94 | -368.70 | -172.05 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 33.88 | 0.00 | 0.00 |
| Price / BV (X) | -1.50 | -1.12 | -1.64 | -4.41 | -1.54 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 33.98 | 0.00 | 0.00 |
| EarningsYield | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
After reviewing the key financial ratios for Gayatri BioOrganics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -72.65. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -72.65, marking a decrease of 72.56.
- For Diluted EPS (Rs.), as of Mar 25, the value is -72.65. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -72.65, marking a decrease of 72.56.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 3. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -4.55. It has decreased from -4.46 (Mar 24) to -4.55, marking a decrease of 0.09.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -4.55. It has decreased from -4.46 (Mar 24) to -4.55, marking a decrease of 0.09.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.05. This value is below the healthy minimum of 2. It has increased from -0.06 (Mar 24) to -0.05, marking an increase of 0.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.05. This value is below the healthy minimum of 0. It has increased from -0.06 (Mar 24) to -0.05, marking an increase of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 0. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 2. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.38. This value is below the healthy minimum of 10. It has decreased from 1.65 (Mar 24) to 1.38, marking a decrease of 0.27.
- For Return On Assets (%), as of Mar 25, the value is -43.67. This value is below the healthy minimum of 5. It has decreased from -43.18 (Mar 24) to -43.67, marking a decrease of 0.49.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 0.2. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is -1.03. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded -1.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.62. This value is below the healthy minimum of 3. It has increased from -3.56 (Mar 24) to -1.62, marking an increase of 1.94.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1.62. This value is below the healthy minimum of 3. It has increased from -3.56 (Mar 24) to -1.62, marking an increase of 1.94.
- For Enterprise Value (Cr.), as of Mar 25, the value is 90.61. It has increased from 75.80 (Mar 24) to 90.61, marking an increase of 14.81.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -201.50. This value is below the healthy minimum of 5. It has decreased from -142.51 (Mar 24) to -201.50, marking a decrease of 58.99.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is -1.50. This value is below the healthy minimum of 1. It has decreased from -1.12 (Mar 24) to -1.50, marking a decrease of 0.38.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded -0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gayatri BioOrganics Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.38% (Industry Average ROCE: 40.7%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 0%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1.62
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.04
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 0)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -1.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Cellulose Derivatives | B3, 3rd Floor, 6-3-1090, Rajbhavan Road, Hyderabad Telangana 500082 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. T V Sandeep Kumar Reddy | Chairman & Non-Exe.Director |
| Mr. K Sreedhara Reddy | Whole Time Director |
| Mrs. Meenakshi Ramchand Sachdeva | Independent Director |
| Mr. P V Narayana Rao | Independent Director |
| Mr. Srinivas Iduri | Independent Director |
FAQ
What is the intrinsic value of Gayatri BioOrganics Ltd?
Gayatri BioOrganics Ltd's intrinsic value (as of 05 January 2026) is ₹8.48 which is 46.67% lower the current market price of ₹15.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹126 Cr. market cap, FY2025-2026 high/low of ₹20.0/5.35, reserves of ₹-115.16 Cr, and liabilities of ₹1.67 Cr.
What is the Market Cap of Gayatri BioOrganics Ltd?
The Market Cap of Gayatri BioOrganics Ltd is 126 Cr..
What is the current Stock Price of Gayatri BioOrganics Ltd as on 05 January 2026?
The current stock price of Gayatri BioOrganics Ltd as on 05 January 2026 is ₹15.9.
What is the High / Low of Gayatri BioOrganics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gayatri BioOrganics Ltd stocks is ₹20.0/5.35.
What is the Stock P/E of Gayatri BioOrganics Ltd?
The Stock P/E of Gayatri BioOrganics Ltd is .
What is the Book Value of Gayatri BioOrganics Ltd?
The Book Value of Gayatri BioOrganics Ltd is 4.62.
What is the Dividend Yield of Gayatri BioOrganics Ltd?
The Dividend Yield of Gayatri BioOrganics Ltd is 0.00 %.
What is the ROCE of Gayatri BioOrganics Ltd?
The ROCE of Gayatri BioOrganics Ltd is 40.7 %.
What is the ROE of Gayatri BioOrganics Ltd?
The ROE of Gayatri BioOrganics Ltd is %.
What is the Face Value of Gayatri BioOrganics Ltd?
The Face Value of Gayatri BioOrganics Ltd is 10.0.